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Introduction: The 5-year overall survival rate of patients undergo-
ing complete surgical resection of pulmonary metastases (PM) from 
colorectal cancer (CRC) and sarcoma remains low (20–50%). Local 
recurrence rate is high (48–66%). Isolated lung perfusion (ILuP) 
allows the delivery of high-dose locoregional chemotherapy with 
minimal systemic leakage to improve local control.
Methods: From 2006 to 2011, 50 patients, 28 male, median age 57 
years (15–76), with PM from CRC (n = 30) or sarcoma (n = 20) were 
included in a phase II clinical trial conducted in four cardiothoracic 
surgical centers. In total, 62 ILuP procedures were performed, 12 
bilaterally, with 45 mg of melphalan at 37°C, followed by resection 
of all palpable PM. Survival was calculated according to the Kaplan–
Meier method.
Results: Operative mortality was 0%, and 90-day morbidity was 
mainly respiratory (grade 3: 42%, grade 4: 2%). After a median fol-
low-up of 24 months (3–63 mo), 18 patients died, two without recur-
rence. Thirty patients had recurrent disease. Median time to local 
pulmonary progression was not reached. The 3-year overall survival 
and disease-free survival were 57% ± 9% and 36% ± 8%, respec-
tively. Lung function data showed a decrease in forced expiratory 
volume in 1 second and diffusing capacity of the alveolocapillary 
membrane of 21.6% and 25.8% after 1 month, and 10.4% and 11.3% 
after 12 months, compared with preoperative values.
Conclusion: Compared with historical series of PM resection with-
out ILuP, favorable results are obtained in terms of local control 
without long-term adverse effects. These data support the further 
investigation of ILuP as additional treatment in patients with resect-
able PM from CRC or sarcoma.
Key Words: Isolated lung perfusion, Local control, Lung metastases, 
Survival, Combined modality treatment.
(J Thorac Oncol. 2014;9: 1547–1553)
The 5-year overall survival (OS) of patients with pulmo-nary metastases (PM) from colorectal carcinoma (CRC) 
and sarcoma remained almost the same over the last 20 years, 
despite improvement in systemic chemotherapy and a better 
preoperative selection. This ranges for CRC between 39% and 
68%1–9 and for sarcoma between 22% and 50%.1,9–14
One of the reasons for this rather poor survival rate is 
the high rate of local recurrence in the operated lung, despite 
complete resection, which ranges between 43% and 66% as 
reported in a large retrospective study1 and also in our own 
institution.15 Recurrence is a significant problem because 
a number of patients will not tolerate a second operation, 
whereas those who can will have a further decline of their 
lung function parameters.16,17 Systemic chemotherapy for PM 
is limited by its systemic side effects and does not result in 
permanent control or cure of these lesions.
Isolated lung perfusion (ILuP) is a surgical technique 
currently evaluated as an adjuvant treatment during thoracot-
omy to reduce the incidence of local pulmonary recurrence. 
With this technique, the lung is completely isolated from the 
systemic circulation by cannulating the pulmonary artery 
and veins. The lung is subsequently perfused with high-dose 
chemotherapy, with minimal systemic leakage.18 It allows the 
chemotherapeutic agent to reach a much higher tissue concen-
tration compared with systemic treatment,19,20 exploiting the 
steep dose–response curve. This technique proved to be safe 
and reproducible.18,21
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Melphalan is an alkylating agent. It has been used for 
decades in the treatment of melanoma with isolated limb perfu-
sion.22–24 However, it is also used in isolated limb perfusion for 
soft-tissue sarcoma,25 in isolated liver perfusion for metasta-
ses of colorectal cancer,26 and for hyperthermic intraperitoneal 
chemotherapy in the treatment of peritoneal carcinomatosis.27 
This makes melphalan one of the most extensively investi-
gated chemotherapeutic agents for isolated organ perfusion, 
with a very well-known pharmacodynamic and pharmacoki-
netic profile. Because of its extensive use in isolated organ 
perfusion and because ILuP with melphalan yielded in an ani-
mal setting the highest efficacy for both PM of carcinoma28 
and sarcoma,20 a clinical phase I trial was started in 2001.21,29 
In this clinical phase I trial, patients with resectable PM from 
a variety of cancers were treated with ILuP with melphalan 
followed by complete lung metastasectomy.21,29 Patients were 
perfused with an increasing dose of melphalan under nor-
mothermic (37°C) or hyperthermic (42°C) conditions.21,29 In 
this phase I clinical trial, followed by an extension trial, the 
maximum tolerated dose was set at 45 mg melphalan at a tem-
perature of 37°C.21,29 Recently, the long-term follow-up of this 
phase I trial has been reported showing no long-term pulmo-
nary toxicity and a 5-year OS of 54.8%.30
Because of the results of this phase I clinical trial and the 
suggested feasibility of ILuP with melphalan for the improve-
ment of local control in patients with resectable PM, a phase II 
clinical trial was started. This study presents the results of this 
multicenter phase II study of ILuP with 45 mg melphalan at 
37°C for patients with resectable PM from CRC and sarcoma.
PATIENTS AND METHODS
From September 2006 until May 2011, a phase II 
clinical trial of ILuP with melphalan was conducted in four 
cardiothoracic centers in the Netherlands and Belgium: St. 
Antonius Hospital, Nieuwegein; Leiden University Medical 
Center, Leiden; Erasmus MC, Rotterdam, the Netherlands; 
and Antwerp University Hospital, Edegem, Belgium.
Study Protocol
The study protocol was approved by all four ethical 
committees of the different participating centers. Primary 
end-point of the study was time to progression (TTP) locally 
advance or metastatic. Secondary end-points were OS and 
pulmonary toxicity. For the inclusion and exclusion criteria, 
see Table 1.
Patients
A total of 50 patients with PM of osteosarcoma, soft-
tissue sarcoma, or CRC were included in this study. A written 
informed consent was obtained from all patients.
Technique
The technique was the same as applied in our phase I 
clinical trial with melphalan and was reported in detail.21 In 
short, patients underwent a thoracotomy. The PM were identi-
fied by bimanual palpation of the lung, and if no histological 
proof was present, a frozen section was performed to confirm 
the presence of metastatic disease. Possible other lesions were 
marked. Heparin was given to reach an activated clotting 
time of 200 seconds. The lung was isolated by cannulating 
the pulmonary artery and the two pulmonary veins with cen-
tral clamping and snaring of the main bronchus to block the 
bronchial arterial circulation. This resulted in a closed circuit. 
Perfusion was performed with a centrifugal pump with the 
mean pulmonary artery pressure before clamping as maxi-
mum accepted pressure. Perfusion was performed at 37°C 
with 45 mg melphalan fixed dose for 30 minutes followed by a 
5-minute washout. Afterward, the PM were resected followed 
by a systematic lymph node dissection. If bilateral disease 
was present, a staged bilateral thoracotomy took place within 
a period of 4–6 weeks. None of the patients received adjuvant 
systemic chemotherapy after the ILuP procedure.
TABLE 1.  Inclusion and Exclusion Criteria
Inclusion Criteria Exclusion Criteria
1 Histologic, cytologic, or 
strong radiographic 
evidence of lung 
metastases from 
colorectal carcinoma, 
osteosarcoma, or soft- 
tissue sarcoma
Uncontrollable infectious 
disease
2 All metastatic diseases 
assessed by radiologic 
examination were 
resectable
Severe comorbidity
3 All metastatic diseases 
were confined to the 
lungs
Previous thoracotomy or 
pleuropulmonary diseases 
resulting in obliteration of 
the pleural space
4 Primary site has been 
radically treated and has 
no signs of recurrence
Pregnancy or lactation
5 Patients had adequate 
cardiac and pulmonary 
reserve to undergo 
a thoracotomy and 
metastasectomy
6 No comorbid conditions 
are present that prevent 
an operation
7 No more than 10 
metastases are present 
in one lung
8 No standard treatment 
options available, 
besides pulmonary 
metastasectomy
9 Performance status ECOG 
0–1
10 Normal renal and liver 
function
11 Adequate bone marrow 
reserve; absolute 
neutrophil count more 
than 2 × 10E9/L and a 
platelet count of more 
than 150 × 10E9/L
ECOG, Eastern Cooperative Oncology Group.
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Follow-Up
Postoperatively, the patients were evaluated by using the 
Cancer Therapy Evaluation Program, Common Terminology 
Criteria for Adverse Events (Version 3.0, DCTD, NCI, NIH, 
DHHS March 31, 2003[http://ctep.cancer.gov]). The first-year 
follow-up was done by the thoracic surgeon and referring phy-
sician at 1, 3, 6, 9, and 12 months. After 1 year, follow-up was 
left to the discretion of the referring physician.
Disease recurrence was evaluated by chest computed 
tomography (CT) at 3, 6, 9, and 12 months after the opera-
tion and thereafter according to local practice. Lung function 
was assessed by forced expiratory volume in 1 second, total 
lung capacity, diffusing capacity of the alveolocapillary mem-
brane (DLCO), and vital capacity. These pulmonary function 
tests were determined at 0, 1, 3, 6, and 12 months to evaluate 
pulmonary toxicity. Follow-up time, OS, disease-free survival 
(DFS), and TTP were recorded. In this study, follow-up was 
determined by last contact with home physician or referring 
physician at the end of 2012, when a median follow-up of at 
least 2 years was achieved.
To evaluate local pulmonary control, local pulmonary 
progression-free survival (PPFS) and the time to local pul-
monary progression (TTLPP) in the perfused lung were also 
recorded. TTLPP was the time period starting the day of the 
perfusion till the development of local pulmonary recurrence 
calculated for each perfused lung, and is purely a measure of 
local control and does not take into account extrapulmonary 
recurrences. For PPFS, local pulmonary recurrence was taken 
as event for each perfused lung.
Statistical Analysis
Mann–Whitney U test was used to evaluate differences 
between the CRC and sarcoma groups for patient character-
istics age. Kaplan–Meier method was used to calculate OS, 
overall median survival time (MST), DFS, TTP, PPFS, and 
TTLPP. The log-rank test was used to determine the effect of 
number of metastases, length of disease-free interval (DFI = 
time between primary tumor and the diagnosis of metastases), 
and histology on OS and DFS, with p less than or equal to 
0.05 for significance. Multivariate analysis was performed 
with Cox regression analysis. All survival data were reported 
with standard error or 95% confidence interval (CI).
RESULTS
Patient Characteristics
Patient characteristics are listed in Table 2. A total of 62 
ILuPs, 12 bilaterally, were performed in 50 patients. Thirty 
had PM from CRC, of which n = 15 had rectal carcinoma 
as primary tumor. Twenty patients had sarcoma as primary 
tumor. Seven of these patients had osteosarcoma as primary 
tumor, of which one was a high-grade Paget’s sarcoma. The 
other 13 sarcoma were as follows: n = 2 chondrosarcoma, n = 4 
not otherwise specified sarcoma, n = 3 fibrosarcoma, n = 2 
synovial sarcoma, and n = 2 leiomyosarcoma. All perfusions 
could be performed without technical difficulties, except for 
one were the centrifugal pump temporarily stopped due to low 
volume in the circuit, which was subsequently corrected.
Fifteen patients (all CRC) were treated for other metas-
tases before they underwent their treatment for PM with ILuP 
and metastasectomy; no sarcoma patients were treated for 
metastases on other locations.
A significant difference was found between the age of 
osteosarcoma patients and the age in the other groups, in which 
the osteosarcoma were younger (p < 0.01 for all groups).
The number of resected PM in one lung ranged from 1 
to 10 with an overall mean of 2.7 and an overall median of 2. 
For CRC, it ranged from 1 to 8 with a mean of 2.1 (95% CI, 
1.5–2.8) and a median of 1. For sarcoma, it ranged from 1 to 
10 with a mean of 3.6 (95% CI, 2.2–5.0) and a median of 3. 
No statistical significant difference was found in the number 
of PM in one lung between CRC and sarcoma (p = 0.09).
The preoperative workup with conventional or helical 
chest CT scan of the 62 perfusions identified n = 28 with one 
PM, n = 14 with two PM, and n = 20 with more than two PM 
in one lung. On postoperative pathology report, six of the 28 
with one PM, two of the 14 with two PM, and five of the 20 
with more than two PM in one lung had more PM resected 
than preoperative identified by the radiographic investiga-
tions. So, in 21.0% of the interventions, more metastatic nod-
ules were detected than suspected preoperatively.
In total, 20 patients had bilateral PM. Eight of these 
20 patients underwent only a perfusion on one side (five 
TABLE 2.  Characteristics of Patients Undergoing Isolated 
Lung Perfusion
Overall CRC Sarcoma
Sex
  Male 28 17 11
  Female 22 13 9
Agea 53 yr (18–76 yr) 59 yr (39–75 yr) 43 yr (18–76 y)
DFI
  ≤36 mo 35 21 14
  >36 mo 15 9 6
Preoperative chemotherapy or radiotherapy
  CT 16 14 2
  RT 2 0 2
  CT + RT 4 4 0
Other metastases treated
  Liver 12 12 0
  Abdominal wall 2 2 0
  Adnexal 1 1 0
Location of metastases
  Unilateral 30 18 12
  Bilateral 20 12 8
Perfusion
  Unilateral 38 23 15
  Bilateral 12 7 5
No. of metastases
  ≤2 32 22 10
  >2 18 8 10
aMean age.
CRC, colorectal cancer; DFI, disease-free interval; CT, chemotherapy; RT, radiotherapy.
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CRC, two synovial sarcoma, and one fibrosarcoma). Five of 
those eight patients underwent a regular thoracotomy with 
metastasectomy on the other side, whereas three did not 
because of development of progressive, unresectable dis-
ease after first ILuP (one CRC, one fibrosarcoma, and one 
synovial sarcoma).
After resection of multiple PM in one of the patients, 
one lesion considered to be a metastasis proved to be a T1 pri-
mary lung adenocarcinoma, which was completely resected. 
One patient was lost to follow-up 7 months after perfusion.
Mortality and Survival
Operative mortality was 0%. After a median follow-up 
of 24 months (3–63 mo), 18 patients died, two without radio-
graphic evidence of recurrence. Cause of death was progres-
sive disease in 16 patients, whereas the cause of death in the 
two patients that died without recurrence was unknown. The 
3-year OS for all patients was 57% ± 9% (Fig. 1). The MST 
for all patients in this study was 44 months (95% CI, 30–58). 
The separate survival data for CRC and sarcoma are shown 
in Table 3.
Recurrent Disease and Disease-Free Survival
Thirty patients (60%) had recurrent disease. Most 
patients developed their initial progressive disease outside 
the perfused lung (23 patients; 77%), whereas only 23% had 
their initial recurrence in the perfused lung. Location of the 
first recurrence is depicted in Table 4. The 3-year DFS for all 
patients was 36% ± 8%. The median TTP for all patients was 
16 months (95% CI, 7–25). During follow-up, a total of 11 
patients developed recurrent disease inside the perfused lung 
of which one patient in both perfused lungs. The 3-year PPFS 
for all patients was 79% ± 6%, and median TTLPP was not 
reached. The separate DFS and TTLPP data for CRC and sar-
coma are lined in Table 3.
Morbidity
In total, 19 patients, five bilateral perfusions, experi-
enced a grade 3 (n = 24) or grade 4 toxicity (n = 1) during the 
first 90 postoperative days. This 90-day morbidity consisted of 
cardiac grade 3 (n = 1, 2%), respiratory grade 3 (n = 21, 42%) 
and grade 4 (n = 1, 2%), gastrointestinal grade 3 (n = 1, 2%), 
and bleeding grade 3 (n = 1, 2%).
Lung Function
Lung function data showed a decrease in vital capac-
ity, total lung capacity, forced expiratory volume in 1 second, 
and diffusing capacity of the alveolocapillary membrane of 
22.3%, 18.8%, 21.6%, and 25.8% after 1 month, and 7.9%, 
11.1%, 10.4%, and 11.3% after 12 months, respectively, com-
pared with preoperative values (Fig. 2).
Univariate Survival Analysis
Overall survival.
There was a significant better OS for patients with CRC 
metastases compared with sarcoma (p < 0.01). Gender did not 
influence OS (p = 0.43). No difference was found for patients 
with a DFI of more than 36 months compared with patients 
with a DFI less than or equal to 36 months (p = 0.43). Patients 
with less than or equal to two PM had a significant better OS 
(p = 0.02) compared with patients with more than two PM. No 
significant difference was found between patients with uni-
lateral or bilateral PM (p = 0.06). The history of treated liver, 
abdominal wall, or adnexa metastases in patients with CRC 
PM did not influence OS after ILuP.
Disease-free survival.
The DFS was not different between patients with CRC 
metastases and sarcoma (p = 0.15). Female patients did it bet-
ter compared with males (p = 0.02). A DFI of more than 36 
months resulted in a better DFS compared with a DFI less 
than or equal to 36 months (p = 0.01). Patients with less than 
or equal to two PM had a significant better DFS compared 
with more than two PM (p < 0.01). No significant difference 
was found between patients with unilateral or bilateral PM 
(p = 0.06). The history of treated liver, abdominal wall, or 
adnexa metastases in patients with CRC lung metastases did 
not influence DFS after ILuP.
Multivariate Survival Analysis
Multivariate analysis was performed for OS and DFS 
with the following variables: gender, age, tumor type, DFI, 
and number of metastases in one lung.
Regarding OS, patients with sarcoma PM had a sig-
nificant lower survival compared with CRC (p < 0.01) with 
a hazard ratio of 5.20 (95% CI, 1.69–15.95). Patients with 
more than 2 PM in one lung had a significant lower chance 
of survival in comparison to less than or equal to two PM in 
one lung (p = 0.02) with a hazard ratio of 4.85 (95% CI, 1.23–
19.12). No other variables were found to be significant.
Regarding DFS, males had a lower DFS in comparison 
to females (p = 0.03) with a hazard ratio of 2.70 (95% CI, 
1.08–6.77). Patients with more than two PM in one lung had 
a significant lower DFS in comparison to less than or equal to 
FIGURE 1.  Kaplan–Meier overall survival curve for all 
patients.
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two PM in one lung (p < 0.01) with a hazard ratio of 3.64 (95% 
CI, 1.40–9.42). No other variables were significant.
DISCUSSION
This article reports the results of the first prospective 
multicenter phase II clinical trial treating patients with resect-
able PM from CRC and sarcoma with a lung metastasectomy 
combined with ILuP. This trial was organized because the 
phase I trial showed that the combination of a resection of PM 
through thoracotomy and ILuP was safe and feasible up to a 
dose of melphalan of 45 mg at a temperature of 37°C in all 
participating centers.21,29
One of the goals of this trial was the confirmation of the 
safety of this technique at the chosen dose of melphalan of 
45 mg perfused at a temperature of 37°C and to evaluate local 
pulmonary control and DFS after thoracotomy with pulmo-
nary metastasectomy combined with ILuP.
The 90-day morbidity in this study only showed well-
known postoperative complications, which are also not uncom-
mon after a routine thoracotomy with metastasectomy without 
ILuP, whereas we did not encounter any procedural mortality 
or excess morbidity compared with historical controls.2,3,31,32 
Therefore, the combination of a thoracotomy with ILuP sug-
gests no increased risk in 90-day morbidity as compared with 
a metastasectomy without ILuP. In addition, two other param-
eters showed no additional negative effect of adding ILuP to 
a thoracotomy. First, the decrease in lung function stabilized 
in time and even slightly improved showing no long-term pul-
monary toxicity of the ILuP procedure. These data are in line 
with the lung function data found in the initial phase I study.30 
Second, no difference in quality of life was found between 
TABLE 3.  Survival Data According to Pathological Diagnosis
3-Year OS MSTa (95% CI) 3-Year DFS Median TTPa (95% CI) 3-Year PPFS Median TTLPPa (95% CI)
All patients 57% ± 9% 44 (30–58) 36% ± 8% 16 (7–25) 79% ± 6% NR
CRC 62% ± 13% NR 41% ± 11% 21 (2–40) 72% ± 8% NR
Sarcoma 48% ± 12% 30 (8–51) 27% ± 10% 8 (6–10) 90% ± 7% 44 (11–77)
aMonths.
OS, overall survival; MST, median survival time; CI, confidence interval; DFS, disease-free survival; TTP, time to progression; PPFS, pulmonary progression-free survival; TTLPP, 
time to local pulmonary progression; CRC, colorectal cancer; NR, not reached.
TABLE 4.  Location of First Recurrence
Location of Recurrence Perfused Lung Contralateral Lung Liver Brain Primary Site Multiple Sites Other
No. of patients 7 10 3 4
% of total patients 14% 20% 6% 4% 2% 6% 8%
% of total recurrence 23% 33% 10% 7% 3% 10% 13%
FIGURE 2.  Postoperative lung function compared 
with the preoperative value (100%). VC, vital 
capacity; FEV1, forced expiratory volume in 1 sec-
ond; DLCO, diffusing capacity of the alveolocapil-
lary membrane; TLC, total lung capacity.
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a standard thoracotomy with metastasectomy compared with 
thoracotomy with metastasectomy and ILuP.33 These results 
confirm that the combination of ILuP with metastasectomy is 
a safe procedure.
This trial strongly suggests an additional positive effect 
of an ILuP procedure compared with a thoracotomy-only 
strategy because of the low percentage (only 23%) of local 
pulmonary recurrent disease. Numbers known from the cur-
rent international literature are higher, 43% for CRC and 66% 
for sarcoma,1 but this is also true for our own historical series, 
50% and 56%, respectively.15 There are only few studies that 
report PPFS or TTLPP with a PPFS of 3 years of 49%8 and 
a TTLPP of 19.4 months,2 both for CRC. In our study, the 
3-year PPFS was 72% ± 8%, and the median TTLPP was not 
reached for CRC.
This is the first time that such a substantial improvement 
in local pulmonary control is demonstrated in an ILuP trial 
but has to be confirmed in subsequent trials, preferentially a 
randomized trial between thoracotomy only and thoracotomy 
with ILuP.
In the literature, the median TTP ranged from 13 to 26 
months,4,5,34 MST from 31 to 72 months,4,5,34 3-year OS from 
56% to 78%,5,35–37 and 3-year DFS from 28% to 44%4,36 for 
CRC. For sarcoma, the median TTP ranged from 7 to 20 
months,12,38,39 MST from 19 to 64 months,12–14,38–41 3-year OS 
from 31% to 71%,12–14,39,40,42,43 and 3-year DFS from 17% to 
26%.39,42 These results are comparable to our results. Despite 
the fact that the local pulmonary control was improved, the 
median TTP and DFS in our study were comparable but not 
better than the best reported in the literature. This emphasizes 
that there is also a need for improved systemic control as meta-
static disease is not only a regional but also a systemic disease.
In this trial, the history of previous metastatic disease 
in the liver or intra-abdominal metastases from a CRC did not 
influence both OS and DFS after ILuP. This is confirmed in 
other studies.44–46
Although there was an extensive preoperative radio-
graphic workup with conventional or high-resolution chest 
CT scan for every patient, the number of PM was underesti-
mated in 21% (n = 13) of the procedures. This is supported by 
other reports, showing that even in 26% to 36% of the cases, 
the number of preoperative identified PM on conventional or 
high-resolution chest CT scan was lower than the number of 
PM found during the operation and found on pathological 
investigation.47,48 These data, together with our results, sug-
gests the need of manual palpation of the lung during lung 
metastasectomy to identify all PM.
Given the zero mortality, the low morbidity, and sug-
gested improved local pulmonary control, an extension trial 
is now running to include another 50 patients for further con-
firmation of these positive findings. For this extension trial, 
four centers are participating in Belgium and the Netherlands. 
After completion, other chemotherapeutic drugs will be eval-
uated in the setting of ILuP to determine their efficacy com-
pared with melphalan in patients with metastases from CRC 
and sarcoma tumors.
Because ILuP can only be performed once in every 
lung, other less invasive techniques are under investigation. 
The aim of these techniques is to be able to give multiple ses-
sions of chemotherapy very selective to the lung to further 
enhance local pulmonary control. One of these techniques 
is selective pulmonary artery perfusion (SPAP).49 With this 
technique, a balloon catheter is introduced into the femoral 
vein and brought up into the pulmonary artery, and a chemo-
therapeutic agent can be injected. To enhance the uptake, a 
balloon is insufflated (blood flow occlusion) which allows the 
chemotherapeutic agent to diffuse into the lung.50 SPAP with 
melphalan is compared with ILuP with melphalan in a rodent 
model, showing similar results in lung tissue levels of melpha-
lan and local control and OS.20 Until now, no clinical studies 
using SPAP with blood flow occlusion are reported.
This study also has some limitations. There was not 
always control of the preoperative treatment patients received 
and the waiting period between the development of PM and 
the metastasectomy. Twenty patients received a wide variety 
of different chemotherapeutic treatments before they were 
included in our study. This was due to the fact that some 
patients were referred from peripheral centers. These different 
treatments could have had a negative impact on lung function, 
diffusion capacity, and physical status preoperatively.
CONCLUSION
In conclusion, this is the first report of a phase II clini-
cal trial of ILuP used in combination with metastasectomy 
for patients with resectable PM from CRC and sarcoma. The 
results show an improved local pulmonary control without 
mortality and with the same morbidity as compared with 
previous literature on metastasectomy without ILuP. This is 
another incentive for the use of ILuP with metastasectomy in 
the treatment of patients with resectable PM. However, this 
needs to be confirmed in randomized trial comparing routine 
thoracotomy and metastasectomy with or without ILuP.
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